Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $21.83 Consensus Price Target from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $21.40.

Several equities research analysts recently issued reports on the stock. TD Cowen lifted their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd. B. Riley Financial lifted their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. Wall Street Zen lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright lifted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $16.58 on Friday. The stock’s 50-day simple moving average is $16.50 and its 200 day simple moving average is $17.36. The firm has a market capitalization of $854.70 million, a PE ratio of 7.54 and a beta of 0.17. Theravance Biopharma has a twelve month low of $10.44 and a twelve month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, analysts anticipate that Theravance Biopharma will post 1.54 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its position in Theravance Biopharma by 78.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 213,104 shares of the biopharmaceutical company’s stock valued at $3,111,000 after buying an additional 93,591 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new stake in Theravance Biopharma in the 3rd quarter valued at $4,536,000. WINTON GROUP Ltd purchased a new stake in Theravance Biopharma in the 3rd quarter valued at $1,118,000. UBS Group AG raised its position in Theravance Biopharma by 10.9% in the 4th quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock valued at $10,673,000 after buying an additional 56,255 shares during the last quarter. Finally, Ellsworth Advisors LLC purchased a new stake in Theravance Biopharma in the 4th quarter valued at $670,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.